Cargando…

Mutant p53 as a guardian of the cancer cell

Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantovani, Fiamma, Collavin, Licio, Del Sal, Giannino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329812/
https://www.ncbi.nlm.nih.gov/pubmed/30538286
http://dx.doi.org/10.1038/s41418-018-0246-9
_version_ 1783386874825408512
author Mantovani, Fiamma
Collavin, Licio
Del Sal, Giannino
author_facet Mantovani, Fiamma
Collavin, Licio
Del Sal, Giannino
author_sort Mantovani, Fiamma
collection PubMed
description Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability. Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53 pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress, metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53 may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations.
format Online
Article
Text
id pubmed-6329812
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-63298122019-01-17 Mutant p53 as a guardian of the cancer cell Mantovani, Fiamma Collavin, Licio Del Sal, Giannino Cell Death Differ Review Article Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability. Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53 pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress, metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53 may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations. Nature Publishing Group UK 2018-12-11 2019-02 /pmc/articles/PMC6329812/ /pubmed/30538286 http://dx.doi.org/10.1038/s41418-018-0246-9 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Mantovani, Fiamma
Collavin, Licio
Del Sal, Giannino
Mutant p53 as a guardian of the cancer cell
title Mutant p53 as a guardian of the cancer cell
title_full Mutant p53 as a guardian of the cancer cell
title_fullStr Mutant p53 as a guardian of the cancer cell
title_full_unstemmed Mutant p53 as a guardian of the cancer cell
title_short Mutant p53 as a guardian of the cancer cell
title_sort mutant p53 as a guardian of the cancer cell
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329812/
https://www.ncbi.nlm.nih.gov/pubmed/30538286
http://dx.doi.org/10.1038/s41418-018-0246-9
work_keys_str_mv AT mantovanifiamma mutantp53asaguardianofthecancercell
AT collavinlicio mutantp53asaguardianofthecancercell
AT delsalgiannino mutantp53asaguardianofthecancercell